("4basebio" or the "Company")
Annual General Meeting 2024 ("AGM")
Directorate Change
At the AGM,
The Company also wishes to again draw attention to the investor meeting being held on 2 July 2024, through the Investor Meet Company platform at 10.00am. Investors can sign up to Investor Meet Company for free and register interest here:
https://www.investormeetcompany.com/register-investor
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943Heikki Lanckriet Nominated Adviser Cairn Financial Advisers LLP +44 (0)20 7213 0880 Jo Tuner /Sandy Jamieson BrokerCavendish Capital Markets Limited +44 (0)20 7220 0500Geoff Nash /Charlie Beeson /Nigel Birks Lionsgate Communications (Media Enquiries) +44 (0)77 91892509Jonathan Charles
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.